What are the limitations of the mipss70 v2 0 mf?

While the mipss70 v2 0 mf is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the mipss70 v2 0 mf to ensure safe bedside use and optimal diagnostic accuracy.

How does the mipss70 v2 0 mf compare to other Hematology scores?

The mipss70 v2 0 mf is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the mipss70 v2 0 mf free to use?

Yes. OpiCalc provides the mipss70 v2 0 mf completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

927 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

MIPSS70+ v2.0 (MF)

MIPSS70+ v2.0: Mutation and Karyotype-enhanced IPSS for Primary Myelofibrosis. Essential for transplant timing in candidates ≤ 70 years.

Clinical Features

Genetic & Molecular

Cytogenetic Risk Class

MIPSS70+ v2.0 Score

0

Risk Category

Low Risk

Estimated Median Survival: > 20 yr

Standard surveillance or targeted therapy (e.g. Ruxolitinib) transition based on symptoms.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Initial risk stratification in patients with Primary Myelofibrosis (PMF) who are candidates for stem cell transplant.

Integrating clinical features with high-risk mutation status (e.g., ASXL1, SRSF2).

Predicting overall survival and leukemia-free survival in the molecular era.

Patient Population

Adult patients with Primary Myelofibrosis (PMF) aged ≤ 70 years. While designed for younger transplant-eligible cohorts, it is the most robust current model.

When Not to Rely on This Score Alone

Secondary MF (e.g., Post-PV/ET MF) — requires different models like MYSEC-PM.

Patients > 70 years — although applicable, transplant decisions differ in older cohorts.

Incomplete molecular data — MIPSS70+ v2.0 requires high-risk mutation profiling (ASXL1, EZH2, SRSF2, U2AF1 Q157) and cytogenetics.

Section 2

Formula & Logic

Clinical Variables

Parameter	Threshold	Points
Anemia	Hb < 10 g/dL	2
Leukocytosis	WBC > 25 × 10⁹/L	1
Blasts	Peripheral blasts ≥ 1%	1
Constitutional	Present	1
Fibrosis	Grade ≥ 2	1

Genetic Variables

Parameter	Condition	Points
Mutation	U2AF1 Q157 mutation	1
HMR Mutation	ASXL1, EZH2, or SRSF2 present	2
High-risk Cyto	Unfavorable / Very High Risk	3-4
Triple Negative	No JAK2/CALR/MPL	2

Risk Groups

Score	Risk Group	Median Survival
0 - 1	Low	Not reached (> 20 yr)
2 - 4	Intermediate	10.3 yr
5 - 8	High	5.0 yr
≥ 9	Very High	1.8 yr

Section 3

Pearls/Pitfalls

Beyond DIPSS-Plus

The MIPSS70+ v2.0 captures the "molecular clock" of myelofibrosis. Patients with low clinical risk but high-risk molecular findings (like SRSF2 or EZH2) may be upstaged and prioritized for early allogeneic transplant.

Section 4

Evidence Appraisal

Primary Score

MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis.

Tefferi A et al. • Journal of Clinical Oncology. 2018;36(17):1769-1770.

View Source

Section 5

Literature

Development

Developed by the Mayo Clinic and international collaborators to replace clinical-only models (IPSS/DIPSS) with a tool that reflects the genomic heterogeneity of myelofibrosis.

Last Comprehensive Review: 2026

Related Hematology Tools

Thrombophilia Screening Eligibility Algorithm

IPSS-R

IPSS-M

WHO 2022 AML Classification Mapper

ELN 2022 AML Risk Classification

Have feedback about this calculator?Let us know.